Hormonal
Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) achieve weight loss magnitudes (15-20%) comparable to bariatric surgery, significantly outperforming older pharmacotherapies and single-agonist GLP-1s.
If you have obesity, newer dual-agonist medications (like tirzepatide) are currently the most effective non-surgical treatment available, offering weight loss results similar to bariatric surgery. They work by targeting multiple hormonal pathways to reduce appetite and improve metabolism. Consult a doctor to see if you qualify based on your BMI and comorbidities.
Clinical trials have demonstrated weight reductions averaging between 15-20% depending on dosage, outcomes comparable to the outcomes historically only achieved with bariatric surgery (16).
Why this rating
Based on Phase 3 RCTs (SURMOUNT-1, SURMOUNT-2) cited in the review.
Source
Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?
Nele Steenackers et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1569468
More from this paper
- Early response to treatment (≥5% weight loss in 3 months) is a strong predictor of long-term success; non-responders should switch therapies.Good
- Combining pharmacotherapy with lifestyle interventions (diet/exercise) or bariatric surgery yields superior weight loss and maintenance compared to either intervention alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →